It has been reported that APR-246 eliminates cancer cells independently of p53 mutations by inducing different cell death pathways, including apoptosis, necroptosis, and ferroptosis, demonstrating that clinical testing of APR-246 should be broadened to include malignancies expressing WT p53, rather than being limited to cancers expressing the mutant p53[54]. The gene discussed is TP53; the disease is cancer.